Monopar Therapeutics director Raymond Anderson sells $351k in stock

Raymond Anderson, a director at Monopar Therapeutics, sold a substantial amount of the company's stock on August 25, 2026, according to a recent SEC Form 4 filing. The total value of the sold stock amounted to $351,189. This sale was made under a pre-established Rule 10b5-1 trading plan, which Anderson created on May 26, 2026. The transaction involved the sale of 3,142 shares of Monopar Therapeutics common stock across three separate transactions.

The shares were sold at varying prices, with the first block of 694 shares sold at a weighted average price of $110.04 per share, the second block of 646 shares at $110.07 per share, and the largest block of 1,802 shares at $113.05 per share. The sale of shares coincides with a remarkable rise in the stock price, with a 227% increase over the past year and an 108% gain in the last six months.

However, InvestingPro analysis indicates that the stock is currently overvalued, trading close to its 52-week high of $124.82. Following the sale, Anderson still holds 23,751 shares of Monopar Therapeutics common stock directly. Recent news about Monopar Therapeutics includes a downgrading of the stock by Cantor Fitzgerald to Neutral from Overweight, as well as an increase in the price target from BTIG to $133.

H.C. Wainwright also raised its price target to $125, emphasizing the progress of a rolling New Drug Application (NDA) for Monopar's drug ALXN1840. Monopar Therapeutics has already submitted the initial sections of the NDA, which allows the FDA to commence the review process. In anticipation of the mid-2026 NDA submission, the company appointed three new commercial executives and added Nicole Sweeny to its Board of Directors.

These developments reflect Monopar's strategic efforts in advancing its drug pipeline and strengthening its commercial leadership.